Distinct forms of DAF in urine and blood

Journal of Immunological Methods

Volumn 260, Issue 1-2, 2002, Pages 43-53

  Miot, Sylvie ^a   Crespo, Sophie ^a   Schifferli, Jürg Alfred ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

ELISA; Human DAF; Plasma; Reticulocytes; Urinary vesicles

Indexed keywords

DECAY ACCELERATING FACTOR;

ARTICLE; BLOOD ANALYSIS; BLOOD CELL; BLOOD CLOTTING; CONTROLLED STUDY; DEPLETION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KIDNEY DISEASE; MEMBRANE VESICLE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DETERMINATION; QUANTITATIVE ASSAY; THROMBOCYTE; URINALYSIS; URINE;

ANTIGENS, CD55; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 0036469804     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(01)00519-1     Document Type: Article

References (30)

1. Origin of a soluble truncated transferrin receptor
2. Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA)
3. A new method for isolation of reticulocytes: Positive selection of human reticulocytes by immunomagnetic separation
4. Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF)
5. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb
6. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery
7. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF)
8. Ectosomes released by human neutrophils are specialized functional units
9. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria
10. Complement receptor 1 (CD35) on human reticulocytes: Normal expression in systemic lupus erythematosus and HIV-infected patients
11. Functional and structural properties of urinary tissue factor
12. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes
13. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids
14. Increased plasma decay-accelerating factor levels in paroxysmal nocturnal hemoglobinuria
15. Isolation of two forms of decay-accelerating factor (DAF) from human urine
16. Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells
17. Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages
18. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system
19. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system
20. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): Measurement by enzyme-linked immunosorbent assay (ELISA)
21. A sensitive sandwich ELISA for measuring erythropoietin in human serum
22. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases
23. Proteolytic cleavage of CR1 on human erythrocytes in vivo: Evidence for enhanced cleavage in AIDS
24. Identification of membrane-bound CR1 (CD35) in human urine: Evidence for its release by glomerular podocytes
25. Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during In vitro maturation of reticulocytes
26. Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 cell infection
27. Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype
28. High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma
29. Comparison of platelet aggregability and P-selectin surface expression on platelets isolated by different methods
30. Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma